Palvella Therapeutics
PVLA
67 hedge funds and large institutions have $133M invested in Palvella Therapeutics in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 2 closing their positions.
1,300% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 2
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
63% more funds holding
Funds holding: 41 → 67 (+26)
7.79% more ownership
Funds ownership: 45.66% → 53.45% (+7.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less capital invested
Capital invested by funds: $143M → $133M (-$10.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.85M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$5.9M |
| 3 |
Morgan Stanley
New York
|
+$2.95M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$2.24M |
| 5 |
CAM
Clio Asset Management
Charlottesville,
Virginia
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$7.97M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.82M |
| 3 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$2.6M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.28M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
-$352K |
PVLA Hedge Fund Activity: Q2 2025 in Review
67 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2025, worth a combined $133M — down 7.1% from $143M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PVLA positions and 2 closed out — a net gain of 26 holders — while 19 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $7.85M. The largest seller was Samsara BioCapital, cutting an estimated $7.97M.
- 67 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2025, up from 41 in Q1 2025.
- Funds reported $133M of Palvella Therapeutics stock for Q2 2025, down 7.1% quarter-over-quarter.
- 28 funds opened new Palvella Therapeutics positions in Q2 2025 and 2 closed out, a net change of +26 holders.
- The largest Palvella Therapeutics buyer in Q2 2025 was BlackRock, an estimated $7.85M added.
- The largest Palvella Therapeutics seller in Q2 2025 was Samsara BioCapital, an estimated $7.97M sold.
Based on aggregated 13F filings for Q2 2025.